- Home
- RGLS
as 10-22-2024 4:00pm EST
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 106.7M | IPO Year: | 2012 |
| Target Price: | $10.33 | AVG Volume (30 days): | 263.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.06 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.08 - $3.79 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Regulus Therapeutics Inc. (RGLS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Collier Kathryn J | RGLS | Director | Jul 25 '24 | Buy | $1.82 | 4,000 | $7,280.00 | 6,740 |
Latest Regulus Therapeutics Inc. News
RGLS Breaking Stock News: Dive into RGLS Ticker-Specific Updates for Smart Investing
MT Newswires
15 days ago
Regulus Therapeutics Completes Enrollment in Phase 1b Kidney Disease Drug Trial
PR Newswire
15 days ago
Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
PR Newswire
2 months ago
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences
Simply Wall St.
2 months ago
Companies Like Regulus Therapeutics (NASDAQ:RGLS) Are In A Position To Invest In Growth
Associated Press Finance
2 months ago
Regulus: Q2 Earnings Snapshot
PR Newswire
2 months ago
Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates
PR Newswire
3 months ago
Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference
MT Newswires
3 months ago
Oppenheimer Initiates Regulus Therapeutics at Outperform With $7 Price Target
Compare RGLS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RGLS Regulus Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.